| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5510189 | Clinical Biochemistry | 2017 | 4 Pages |
Abstract
The EP26-A protocol arrived at the same conclusions as our protocol in 75% of the evaluations and required more samples for 4 of the 6 analytes tested. Challenges associated with determining rejection limits and the need for increased sample sizes may be critical factors that limit the utility of EP26-A.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Brooke M. Katzman, Karl M. Ness, Alicia Algeciras-Schimnich,